After Hours Stock Movers: Tech Surge Leads Monday's Rally

Market Sentiment Shifts Toward Optimism

Wall Street opened its trading week with a distinctly bullish tone on Monday, Nov. 24, wiping away the previous week’s volatility and driving substantial gains across major indices. The Nasdaq Composite (NASDAQINDEX: ^IXIC) climbed 2.69%, adding 599 points, while the S&P 500 (SNPINDEX: ^GSPC) gained 1.55% and the Dow Jones Industrial Average (DJINDICES: ^DJI) rose 0.44% with a 203-point advance. This shift in market psychology provided strong tailwinds for certain sectors, particularly technology stocks that had absorbed considerable selling pressure in recent sessions.

Winners: Tech & Healthcare Lead the Charge

Broadcom Powers Ahead on AI Chip Demand

Semiconductor giant Broadcom (NASDAQ: AVGO) emerged as one of Monday’s standout performers, surging 11% as investors reassessed the company’s position in the artificial intelligence infrastructure buildout. The catalyst came from weekend commentary regarding Alphabet (NASDAQ: GOOGL, GOOG) and its search division’s accelerating AI investments. Since Broadcom supplies critical semiconductor components to major cloud and search companies, positive news about their spending trajectories directly benefits the chipmaker’s order books.

Adding to the optimistic sentiment, Amazon (NASDAQ: AMZN) disclosed plans to allocate tens of billions of dollars toward AI capabilities and infrastructure. For a company like Broadcom with deep exposure to enterprise AI deployments, such announcements translate into tangible business growth catalysts. While concerns persist about the sustainability and peak spending levels in the AI sector, investors appeared focused on near-term tailwinds rather than longer-term cycle questions.

Oscar Health Bounces on Policy Clarity

Oscar Health (NYSE: OSCR) delivered an impressive 22% jump, driven by improving sentiment around healthcare policy. The health insurance provider’s stock had suffered during the October-November government shutdown as investors worried about uncertainty surrounding Affordable Care Act premium subsidies. With the Trump administration signaling a potential pathway to extend these subsidies temporarily, Oscar shareholders saw a tangible reduction in downside risk. While the stock remains substantially below its October peak, this policy development offers renewed hope for improved margins and subscriber retention going forward.

Losers: Mixed Headwinds Trigger Selloffs

Novo Nordisk Stumbles on Failed Alzheimer’s Trial

Novo Nordisk (NYSE: NVO) declined 6% after disappointing clinical trial results for its GLP-1 semaglutide drug in treating Alzheimer’s disease progression. The pharmaceutical company had invested considerable resources in studying whether semaglutide could slow cognitive decline, but the study failed to meet its primary efficacy endpoints. CEO Mike Doustdar attempted to frame the negative outcome as an expected setback given the inherent scientific challenges, yet investors remained discouraged by another unsuccessful attempt to crack the Alzheimer’s therapeutic puzzle. For a company dependent on breakthrough drug development, failed high-profile trials weigh heavily on market sentiment.

Retail Weakness Ahead of Earnings

Abercrombie & Fitch (NYSE: ANF) declined 6% on the back of disappointing guidance concerns. With quarterly earnings due on Tuesday, the apparel retailer faces investor skepticism about near-term consumer spending trends. Mixed signals from the retail sector—including optimistic holiday projections from the National Retail Federation but cautionary guidance from several major chains—have created uncertainty around seasonal demand. Employment concerns and persistent inflation continue to weigh on consumer confidence. Through Monday’s close, Abercrombie & Fitch’s year-to-date performance has deteriorated to a loss exceeding 50%, reflecting broader apparel sector challenges.

Key Takeaways for Investors

The divergent performance among after hours stock movers highlights how sector rotation and specific catalysts continue to drive market dynamics. Technology infrastructure plays benefited from concrete evidence of sustained AI spending from megacap companies, while healthcare and retail names responded more sharply to policy developments and earnings outlooks. Moving forward, investors should monitor whether the AI spending narrative remains intact or faces headwinds from valuation concerns and return-on-investment questions.